Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Proof of Concept community infection study to assess the safety and potential efficacy of INNA-051.

X
Trial Profile

A Phase II Proof of Concept community infection study to assess the safety and potential efficacy of INNA-051.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INNA-051 (Primary)
  • Indications Influenza virus infections; Viral infections
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 10 Feb 2025 According to an Ena Respiratory media release, company received a US$5 million investment from Flu Lab and the investment will support ENA's planned Phase II proof-of-concept trial.
    • 24 Jan 2025 New trial record
    • 22 Jan 2025 According to the ENA Respiratory Media Release, company is currently planning Q4 2025 Phase II community infection study to assess the safety and potential efficacy of INNA-051 in reducing the incidence and duration of symptomatic infections caused by common respiratory viruses, including coronaviruses, seasonal influenza, rhinoviruses, respiratory syncytial virus and human metapneumovirus in young adults at risk for exposure living in the US.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top